WBIO — WPD Pharmaceuticals Share Price
Last trade - 00:00- CA$0.32m
- CA$0.71m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
WPD Pharmaceuticals Inc. is a Canada-based company. The Company is currently not carrying on any active business. It is focused on evaluating opportunities to acquire an interest in an operating business. The Company does not generate revenue.
Directors
- Mariusz Olejniczak CEO
- Michael Malana CFO
- Liam Corcoran VPR
- Romuald Harwas DRC
- Teresa Rzepczyk DRC
- Peter Novak IND
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- July 4th, 2006
- Public Since
- May 26th, 2008
- Sector
- Holding Companies
- Industry
- Financials
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 4,639,485
- Address
- 750 West Pender Street, Suite 401, VANCOUVER, V6C 2T7
- Web
- https://www.wpdpharmaceuticals.com/
- Phone
- +1 6045612687
- Auditors
- Davidson & Company LLP
Upcoming Events for WBIO
Similar to WBIO
Better Plant Sciences
Canadian Securities Exchange
Beyond Medical Technologies
Canadian Securities Exchange
Digicann Ventures
Canadian Securities Exchange
eXeBlock Technology
Canadian Securities Exchange
Gencan Capital
Canadian Securities Exchange
FAQ
As of Today at 24:09 UTC, shares in WPD Pharmaceuticals are trading at CA$0.07. This share price information is delayed by 15 minutes.
Shares in WPD Pharmaceuticals last closed at CA$0.07 and the price had moved by -93.78% over the past 365 days. In terms of relative price strength the WPD Pharmaceuticals share price has underperformed the Toronto Stock Exchange 300 Composite Index by -94.47% over the past year.
There is no consensus recommendation for this security.
Find out moreWPD Pharmaceuticals does not currently pay a dividend.
WPD Pharmaceuticals does not currently pay a dividend.
WPD Pharmaceuticals does not currently pay a dividend.
To buy shares in WPD Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.07, shares in WPD Pharmaceuticals had a market capitalisation of CA$0.32m.
Here are the trading details for WPD Pharmaceuticals:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: WBIO
Based on an overall assessment of its quality, value and momentum WPD Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like WPD Pharmaceuticals. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -44.33%.
As of the last closing price of CA$0.07, shares in WPD Pharmaceuticals were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The WPD Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
WPD Pharmaceuticals' management team is headed by:
- Mariusz Olejniczak - CEO
- Michael Malana - CFO
- Liam Corcoran - VPR
- Romuald Harwas - DRC
- Teresa Rzepczyk - DRC
- Peter Novak - IND